New Triple‑Target CAR T Cells Show Promise in Early Human Trial
The first human study of a new type of CAR T cell, engineered to attack three B‑cell markers—CD19, CD20 and CD22—has produced encouraging safety and effectiveness results. The cells also carry an OX40 signal that helps them stay active in the body. Pre‑clinical work showed that these triple‑specif